DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC notifies Pacira on PCRX deadline

A class action lawsuit has recently been initiated against Pacira BioSciences, Inc. (referred to as Pacira or the Company) and specific officers within the organization. The lawsuit alleges that Pacira made false and misleading statements regarding the efficacy of their product, EXPAREL.

EXPAREL is a non-opioid medication used for postsurgical pain management. According to the lawsuit, Pacira falsely claimed that EXPAREL was superior to traditional opioids in managing pain after surgery. The company allegedly misrepresented the drug’s effectiveness, leading to investors purchasing Pacira stock at inflated prices.

The class action lawsuit claims that Pacira’s statements regarding EXPAREL were misleading and caused financial harm to investors who relied on this false information to make informed decisions about investing in the company. The lawsuit aims to hold Pacira accountable for its alleged misrepresentations and seeks damages for investors who suffered losses as a result.

Investors who purchased Pacira stock between May 5, 2021, and June 29, 2021, are encouraged to participate in the class action lawsuit. The lawsuit seeks to recover financial losses incurred by investors due to Pacira’s alleged false and misleading statements regarding EXPAREL. Investors who have been impacted by these alleged misrepresentations may be entitled to compensation for their losses.

Pacira BioSciences, Inc. is facing legal action as a result of these allegations, and the outcome of the class action lawsuit will determine the consequences for the company and its officers. Investors who have been affected by Pacira’s alleged misrepresentations are seeking justice and accountability for the financial losses they have suffered.

The class action lawsuit against Pacira BioSciences, Inc. highlights the importance of transparency and honesty in the pharmaceutical industry. Investors rely on accurate information to make informed decisions about their investments, and companies must be held accountable for any misleading statements that may harm investors financially. The outcome of this lawsuit will shed light on the allegations made against Pacira and determine the next steps for investors seeking justice for their losses.